The World Market for Liquid Biopsy, 2023

The World Market for Liquid Biopsy, 2023

Dramatic changes have occurred in the liquid biopsy market, necessitating a resource to provide perspective on the market opportunity. This new report from Kalorama assesses the Liquid Biopsy Market now and in 2027. The report can be useful for business planning, market share assessment, competitive research, and due diligence for mergers and acquisitions and other partnerships.

Liquid biopsy is gaining acceptance each year. Even through the COVID-19 pandemic, announcements of new liquid biopsy products were made and studies conducted to assess the capability of these tests in clinical diagnostics uses. While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.

This report, The World Liquid Biopsy Market, 2023, from Kalorama Information, contains up-to-date information and useful data points for business planning:

The Market for Liquid Biopsy by RegionNorth AmericaEuropeAsiaRest of WorldThe Market for CTC-based Liquid BiopsyGrowth to 2027The Market for ctDNA-based Liquid BiopsyGrowth to 2027The Market for EV and Exosome-based Liquid BiopsyGrowth to 2027The Market for Multi-Analyte-based Liquid BiopsyGrowth to 2027The Market for Other Analytes Liquid BiopsyGrowth to 2027Liquid Biopsy Market by Type of Cancer BreastLungColorectalOvarianProstatePan-CancerOther CancerR&D: Selected ctDNA-based Liquid Biopsy Tests in Development

On the Market: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021

On the Market: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:Early detection and diagnosis / screeningAlternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknownTherapy personalization and monitoring – by molecular characterization of a patient’s disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance ariseDisease monitoring – to observe disease progression, tumor evolution, residual disease, and early detection of recurrenceThese applications, increasing acceptance, the use of liquid biopsy in combination with other technologies. This report contains market assessments for these application categories.

In addition, the report profiles key companies in the market, including: Adaptive Biotechnologies Agena Bioscience, Inc. Angle, PLC Aspira Women’s Health Biocartis Group Nv Biocept, Inc. Biodesix Cellmax Life Circulogene Diacarta, Inc. Epic Sciences Epigenomics AG Exact Sciences Exosome Diagnostics, Inc. Foundation Medicine, Inc. (Roche) Freenome, Inc. Gilupi Gmbh Grail (Illumina) Guardant Health, Inc. Hologic Lunglife AI (Formerly Cynvenio Biosystems) Menarini-Silicon Biosystems, SPA Myriad Genetics, Inc. Natera, Inc. Neogenomics Laboratories, Inc. Oncocyte Corporation Oncodna S.A. Personal Genome Diagnostics Qiagen N.V. Cell-Free DNA Technologies Ctc Technologies Exosome And Mirna Technologies Resolution Biosciences (Agilent) Roche Diagnostics Sysmex-Inostics, Inc. Tempus Volitionrx